Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma

Journal of Gastroenterology

Volumn 50, Issue 3, 2015, Pages 323-332

  Iritani, Soichi ^a   Imai, Kenji ^a   Takai, Koji ^a   Hanai, Tatsunori ^a   Ideta, Takayasu ^a   Miyazaki, Tsuneyuki ^a   Suetsugu, Atsushi ^a   Shiraki, Makoto ^a   Shimizu, Masahito ^a   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatocellular carcinoma; Prognostic factor; Sarcopenia; Skeletal muscle depletion; Total body fat free mass

Indexed keywords

TUMOR MARKER;

ADULT; AGED; BLOOD; BODY MASS; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; COMPLICATION; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; KAPLAN MEIER METHOD; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; RADIOGRAPHY; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; SARCOPENIA; SKELETAL MUSCLE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BODY MASS INDEX; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SARCOPENIA; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84929327194     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-014-0964-9     Document Type: Article

References (37)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90 (Epub 2011/02/08).
2. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol. 2002;35(5 Suppl 2):S72–8 (Epub 2002/10/24).
3. op den Winkel M, Nagel D, Sappl J, op den Winkel P, Lamerz R, Zech CJ, et al. Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. PloS One. 2012;7(10):e45066 (Epub 2012/10/17).
4. Tajika M, Kato M, Mohri H, Miwa Y, Kato T, Ohnishi H, et al. Prognostic value of energy metabolism in patients with viral liver cirrhosis. Nutrition. 2002;18(3):229–34 (Epub 2002/03/08).
5. Montano-Loza AJ, Meza-Junco J, Prado CM, Lieffers JR, Baracos VE, Bain VG, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc. 2012;10(2):166–173 e1 (Epub 2011/09/07).
6. Periyalwar P, Dasarathy S. Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses. Clin Liver Dis. 2012;16(1):95–131 (Epub 2012/02/11).
7. Poon RT. Prevention of recurrence after resection of hepatocellular carcinoma: a daunting challenge. Hepatology. 2011;54(3):757–9 (Epub 2011/07/28).
8. Shiraki M, Nishiguchi S, Saito M, Fukuzawa Y, Mizuta T, Kaibori M, et al. Nutritional status and quality of life in current patients with liver cirrhosis as assessed in 2007–2011. Hepatology Res: Off J Jpn Soc Hepatol. 2013;43(2):106–12 (Epub 2013/02/16).
9. Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997;127(5 Suppl):990S–1S (Epub 1997/05/01).
10. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in older people. Age Ageing. 2010;39(4):412–23 (Epub 2010/04/16).
11. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629–35 (Epub 2008/06/10).
12. Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15(22):6973–9 (Epub 2009/11/06).
13. Sabel MS, Lee J, Cai S, Englesbe MJ, Holcombe S, Wang S. Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol. 2011;18(13):3579–85 (Epub 2011/08/09).
14. van Vledder MG, Levolger S, Ayez N, Verhoef C, Tran TC, Ijzermans JN. Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg. 2012;99(4):550–7 (Epub 2012/01/17).
15. Dodson RM, Firoozmand A, Hyder O, Tacher V, Cosgrove DP, Bhagat N, et al. Impact of sarcopenia on outcomes following intra-arterial therapy of hepatic malignancies. J Gastrointest Surg: Off J Soc Surg Aliment Tract. 2013;17(12):2123–32 (Epub 2013/09/26).
16. Mir O, Coriat R, Blanchet B, Durand JP, Boudou-Rouquette P, Michels J, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PloS One. 2012;7(5):e37563 (Epub 2012/06/06).
17. Meza-Junco J, Montano-Loza AJ, Baracos VE, Prado CM, Bain VG, Beaumont C, et al. Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma. J Clin Gastroenterol. 2013;47(10):861–70 (Epub 2013/06/12).
18. Kaido T, Ogawa K, Fujimoto Y, Ogura Y, Hata K, Ito T, et al. Impact of sarcopenia on survival in patients undergoing living donor liver transplantation. Am J Transplant: Off J Am Soc Transplant Am Soc Transpl Surg. 2013;13(6):1549–56 (Epub 2013/04/23).
19. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol (1985). 1998;85(1):115–22 (Epub 1998/07/09).
20. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab = Physiol Appl Nutr Metab. 2008;33(5):997–1006 (Epub 2008/10/17).
21. Clinical Practice Guidelines for Hepatocellular Carcinoma. The Japan Society of Hepatology 2009 update. Hepatol Res: Off J Jpn Soc Hepatol. 2010;40(Suppl 1):2–144 (Epub 2010/07/01).
22. Kudo M, Kubo S, Takayasu K, Sakamoto M, Tanaka M, Ikai I, et al. Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version). Hepatol Res: Off J Jpn Soc Hepatol. 2010;40(7):686–92 (Epub 2010/07/17).
23. The general rules for the clinical and pathological study of primary liver cancer. Liver Cancer Study Group of Japan. Jpn J Surg. 1989;19(1):98–129 (Epub 1989/01/01).
24. Ikai I, Kudo M, Arii S, Omata M, Kojiro M, Sakamoto M, et al. Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol Res. 2010;40(11):1043–59.
25. Merli M, Riggio O, Dally L. Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi). Hepatology. 1996;23(5):1041–6 (Epub 1996/05/01).
26. Imai K, Takai K, Nishigaki Y, Shimizu S, Naiki T, Hayashi H, et al. Insulin resistance raises the risk for recurrence of stage I hepatocellular carcinoma after curative radiofrequency ablation in hepatitis C virus-positive patients: a prospective, case series study. Hepatol Res: Off J Jpn Soc Hepatol. 2010;40(4):376–82 (Epub 2010/03/20).
27. Shimizu M, Tanaka T, Moriwaki H. Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis. Semin Immunopathol. 2013;35(2):191–202 (Epub 2012/09/05).
28. Prado CM, Wells JC, Smith SR, Stephan BC, Siervo M. Sarcopenic obesity: a Critical appraisal of the current evidence. Clin Nutr. 2012;31(5):583–601 (Epub 2012/07/20).
29. Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L. Sarcopenic obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care. 2008;11(6):693–700 (Epub 2008/10/02).
30. Harimoto N, Shirabe K, Yamashita YI, Ikegami T, Yoshizumi T, Soejima Y, et al. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg. 2013;100(11):1523–30 Epub 2013/09/17.
31. Lutz CT, Quinn LS. Sarcopenia, obesity, and natural killer cell immune senescence in aging: altered cytokine levels as a common mechanism. Aging. 2012;4(8):535–46 (Epub 2012/09/01).
32. Jones JC, Coombes JS, Macdonald GA. Exercise capacity and muscle strength in patients with cirrhosis. Liver Transplant: Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 2012;18(2):146–51 (Epub 2011/12/06).
33. Plauth M, Cabre E, Riggio O, Assis-Camilo M, Pirlich M, Kondrup J, et al. ESPEN Guidelines on Enteral Nutrition: liver disease. Clin Nutr. 2006;25(2):285–94 (Epub 2006/05/19).
34. Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C, et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology. 2003;124(7):1792–801 (Epub 2003/06/14).
35. Moriwaki H, Shiraki M, Fukushima H, Shimizu M, Iwasa J, Naiki T, et al. Long-term outcome of branched-chain amino acid treatment in patients with liver cirrhosis. Hepatol Res: Off J Jpn Soc Hepatol. 2008;38(Suppl 1):S102–6 (Epub 2009/01/08).
36. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc. 2005;3(7):705–13 (Epub 2005/10/07).
37. Vincent HK, Raiser SN, Vincent KR. The aging musculoskeletal system and obesity-related considerations with exercise. Ageing Res Rev. 2012;11(3):361–73 (Epub 2012/03/24).